BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 22904352)

  • 1. Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy.
    Berthoux F; Suzuki H; Thibaudin L; Yanagawa H; Maillard N; Mariat C; Tomino Y; Julian BA; Novak J
    J Am Soc Nephrol; 2012 Sep; 23(9):1579-87. PubMed ID: 22904352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrent IgA nephropathy is predicted by altered glycosylated IgA, autoantibodies and soluble CD89 complexes.
    Berthelot L; Robert T; Vuiblet V; Tabary T; Braconnier A; Dramé M; Toupance O; Rieu P; Monteiro RC; Touré F
    Kidney Int; 2015 Oct; 88(4):815-22. PubMed ID: 26061544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression.
    Maixnerova D; Ling C; Hall S; Reily C; Brown R; Neprasova M; Suchanek M; Honsova E; Zima T; Novak J; Tesar V
    PLoS One; 2019; 14(2):e0212254. PubMed ID: 30794576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum galactose-deficient-IgA1 and IgG autoantibodies correlate in patients with IgA nephropathy.
    Placzek WJ; Yanagawa H; Makita Y; Renfrow MB; Julian BA; Rizk DV; Suzuki Y; Novak J; Suzuki H
    PLoS One; 2018; 13(1):e0190967. PubMed ID: 29324897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression.
    Zhao N; Hou P; Lv J; Moldoveanu Z; Li Y; Kiryluk K; Gharavi AG; Novak J; Zhang H
    Kidney Int; 2012 Oct; 82(7):790-6. PubMed ID: 22673888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Both IgA nephropathy and alcoholic cirrhosis feature abnormally glycosylated IgA1 and soluble CD89-IgA and IgG-IgA complexes: common mechanisms for distinct diseases.
    Tissandié E; Morelle W; Berthelot L; Vrtovsnik F; Daugas E; Walker F; Lebrec D; Trawalé JM; Francoz C; Durand F; Moura IC; Paradis V; Moreau R; Monteiro RC
    Kidney Int; 2011 Dec; 80(12):1352-63. PubMed ID: 21866091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy.
    Camilla R; Suzuki H; Daprà V; Loiacono E; Peruzzi L; Amore A; Ghiggeri GM; Mazzucco G; Scolari F; Gharavi AG; Appel GB; Troyanov S; Novak J; Julian BA; Coppo R
    Clin J Am Soc Nephrol; 2011 Aug; 6(8):1903-11. PubMed ID: 21784819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy.
    Wada Y; Matsumoto K; Suzuki T; Saito T; Kanazawa N; Tachibana S; Iseri K; Sugiyama M; Iyoda M; Shibata T
    PLoS One; 2018; 13(11):e0206865. PubMed ID: 30388165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of patients with coexisting IgA nephropathy and membranous nephropathy.
    Chen P; Shi SF; Qu Z; Zhao N; Xie XF; Lv JC; Liu LJ; Zhang H
    Ren Fail; 2018 Nov; 40(1):213-218. PubMed ID: 29619862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glomerular Immunodeposits of Patients with IgA Nephropathy Are Enriched for IgG Autoantibodies Specific for Galactose-Deficient IgA1.
    Rizk DV; Saha MK; Hall S; Novak L; Brown R; Huang ZQ; Fatima H; Julian BA; Novak J
    J Am Soc Nephrol; 2019 Oct; 30(10):2017-2026. PubMed ID: 31444275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Value of Serum Biomarkers of Autoimmunity for Recurrence of IgA Nephropathy after Kidney Transplantation.
    Berthoux F; Suzuki H; Mohey H; Maillard N; Mariat C; Novak J; Julian BA
    J Am Soc Nephrol; 2017 Jun; 28(6):1943-1950. PubMed ID: 28255003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of IgG co-deposition with serum levels of galactose-deficient IgA1 in pediatric IgA nephropathy.
    Eison TM; Hastings MC; Moldoveanu Z; Sanders JT; Gaber L; Walker PD; Lau KK; Julian BA; Novak J; Wyatt RJ
    Clin Nephrol; 2012 Dec; 78(6):465-9. PubMed ID: 23006340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Immunosuppressive Drugs on the Changes of Serum Galactose-Deficient IgA1 in Patients with IgA Nephropathy.
    Kim MJ; Schaub S; Molyneux K; Koller MT; Stampf S; Barratt J
    PLoS One; 2016; 11(12):e0166830. PubMed ID: 27930655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis.
    Suzuki H; Yasutake J; Makita Y; Tanbo Y; Yamasaki K; Sofue T; Kano T; Suzuki Y
    Kidney Int; 2018 Mar; 93(3):700-705. PubMed ID: 29329643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma galactose-deficient immunoglobulin A1 and loss of kidney function in patients with immunoglobulin A vasculitis nephritis.
    Zhang X; Xie X; Shi S; Liu L; Lv J; Zhang H
    Nephrol Dial Transplant; 2020 Dec; 35(12):2117-2123. PubMed ID: 31377786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of serum galactose deficient IgA1 as a potential biomarker for IgA nephropathy: A case control study.
    Bagchi S; Lingaiah R; Mani K; Barwad A; Singh G; Balooni V; Bhowmik D; Agarwal SK
    PLoS One; 2019; 14(3):e0214256. PubMed ID: 30917188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies.
    Tomana M; Novak J; Julian BA; Matousovic K; Konecny K; Mestecky J
    J Clin Invest; 1999 Jul; 104(1):73-81. PubMed ID: 10393701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galactose-deficient IgA1 in African Americans with IgA nephropathy: serum levels and heritability.
    Hastings MC; Moldoveanu Z; Julian BA; Novak J; Sanders JT; McGlothan KR; Gharavi AG; Wyatt RJ
    Clin J Am Soc Nephrol; 2010 Nov; 5(11):2069-74. PubMed ID: 20634323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recognition of galactose-deficient O-glycans in the hinge region of IgA1 by N-acetylgalactosamine-specific snail lectins: a comparative binding study.
    Gomes MM; Suzuki H; Brooks MT; Tomana M; Moldoveanu Z; Mestecky J; Julian BA; Novak J; Herr AB
    Biochemistry; 2010 Jul; 49(27):5671-82. PubMed ID: 20507092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG.
    Tomana M; Matousovic K; Julian BA; Radl J; Konecny K; Mestecky J
    Kidney Int; 1997 Aug; 52(2):509-16. PubMed ID: 9264010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.